To determine if TP53 mutant DLBCL had other aberrantly expressed lineage markers, CD20 and PAX5 immunohistochemistry results were evaluated in CD19 positive lymphomas with TP53 mutations in comparison to CD19 positive lymphomas with wild-type TP53 (Table 2). The gene discussed is PAX5; the disease is lymphoma.